Sort
10,766 grants matching “checkpoint inhibitor”
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,460,954David E Fisher · Massachusetts General Hospital · P01 · FY2013 · CA
A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab
$1,460,952Mohan Rao Kaadige · Stingray Therapeutics, Inc. · R44 · FY2025 · CA
Immunobiology and Immunotherapy of Pediatric Tumors
$1,459,080Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Studies of Receptor Interactions and Effects of Alarmins
$1,449,620Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Control of centrosome biogenesis
$1,448,934Jadranka Loncarek · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
SPORE in Myeloid Malignancies
$1,440,214Benjamin Levine Ebert · Brigham And Women'S Hospital · P50 · FY2018 · CA
Immunobiology and Immunotherapy of Pediatric Cancer
$1,440,159Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer
$1,440,117Angelo Michael De Marzo · Johns Hopkins University · U54 · FY2024 · CA
Molecular Mechanisms Of The Autoimmune Lymphoproliferative Syndrome And Other Immunoregulatory Disorders
$1,438,637Michael J Lenardo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$1,437,228Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Biomolecular Structure and Mechanism, Structure-Based Drug Design
$1,434,621Xinhua Ji · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Rational approaches to melanoma therapy
$1,430,873Meenhard Herlyn · Wistar Institute · U54 · FY2019 · CA
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,430,472David E Fisher · Massachusetts General Hospital · P01 · FY2022 · CA
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,428,421David E Fisher · Massachusetts General Hospital · P01 · FY2023 · CA
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
$1,428,130Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2024 · CA
Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer
$1,425,000Robert Lippert · Kuda Therapeutics, Inc. · R44 · FY2022 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,423,817Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients
$1,420,853Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R44 · FY2025 · CA
TARGETING THE IMMUNOSUPPRESSIVE MICROENVIRONMENT OF PROSTATE CANCER TO ENHANCE THERAPEUTIC EFFICACY OF THE IMMUNE CHECKPOINT INHIBITORS
$1,420,835Icahn School Of Medicine At Mount Sinai · · FY2025 · Defense Health Agency
Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies
$1,420,204Anish Thomas · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Mechanisms of non-classical multidrug resistance in cancer
$1,416,959Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Next generation T cell therapies for mutant KRAS solid tumors
$1,412,213Beatriz M. Carreno · University Of Pennsylvania · UG3 · FY2024 · CA
Integration of Actin Dynamics and Adhesion in Cell Migration
$1,411,479Clare Michal Waterman · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL
Cellular Interactions with Thrombospondin
$1,411,277David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$1,411,211Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2021 · AI